Satellos Presents Interim SAT-3247 Clinical and Biomarker Data in Duchenne Muscular Dystrophy at the 2026 MDA Clinical & Scientific Conference

Core Insights - Satellos Bioscience Inc. announced interim clinical and biomarker data for SAT-3247 at the MDA Clinical & Scientific Conference, highlighting progress in treating degenerative muscle diseases [1][2] Group 1: Clinical Progress - SAT-3247 shows continued improvements in handgrip strength and new muscle measurements through dynamometry [2][4] - Interim observations from the Phase 2 TRAILHEAD study indicate overall stability in elbow and shoulder strength, with greater improvements in participants with higher baseline muscle mass [4][5] - The ongoing BASECAMP study is evaluating SAT-3247 in a pediatric population, focusing on earlier intervention in disease progression [6] Group 2: Biomarker Analysis - A serum proteomic analysis from the completed 28-day Phase 1a/b study revealed consistent biomarker changes after two weeks of SAT-3247 administration, including reductions in established DMD biomarkers [3][5] - The development of a novel regenerative index (RI) based on established biomarkers is being utilized in the BASECAMP study clinical protocol [3] Group 3: Preclinical Findings - Preclinical data in a mouse model of facioscapulohumeral muscular dystrophy (FSHD) demonstrated enhanced muscle strength, supporting the broader clinical potential of SAT-3247 [4][11] - Significant enhancement of muscle strength was observed across a 12-week dosing period, indicating potential applicability beyond DMD [11] Group 4: Company Overview - Satellos is focused on developing SAT-3247 as a novel oral small molecule drug for regenerating skeletal muscle lost in DMD and other degenerative muscle diseases [8][9] - SAT-3247 targets AAK1, a key protein involved in muscle stem-cell signaling, aiming to restore effective muscle regeneration [9]